Company profile

Future of Abbott Laboratories

#
Rank
13
| Quantumrun Global 1000

Abbott Laboratories is one of the world's leaders in the healthcare industry. The company has operated since 1888, since its founding by Chicago physician Wallace Calvin Abbot. Abbott Laboratories has since expanded and started selling medical devices, research-based medications, nutritional supplements, and diagnostics. In 2013, the multinational founded Abbvie to handle all the research-based drugs operations. Today, Abbott Laboratories is headquartered in Lake Bluff, Illinois.

Home Country:
Sector:
Industry:
Medical Products and Equipment
Founded:
1888
Global employee count:
75000
Domestic employee count:
39313
Number of domestic locations:
10

Financial Health

Revenue:
$20853000000 USD
3y average revenue:
$20501666667 USD
Operating expenses:
$17668000000 USD
3y average expenses:
$17618000000 USD
Funds in reserve:
$18620000000 USD
Market country
Revenue from country
0.31
Market country
Revenue from country
0.33

Asset Performance

  1. Product/Service/Dept. name
    Established pharmaceutical
    Product/Service revenue
    3720000000
  2. Product/Service/Dept. name
    Nutritional
    Product/Service revenue
    6975000000
  3. Product/Service/Dept. name
    Diagnostic
    Product/Service revenue
    4646000000

Innovation assets and Pipeline

Investment into R&D:
$550000000 USD
Total patents held:
6254
Number of patents field last year:
45

All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page. 

DISRUPTION VULNERABILITY

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.
*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.
*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.
*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.

COMPANY’S FUTURE PROSPECTS

Company Headlines